Antalarmin blockade of corticotropin releasing
hormone-induced hypertension in rats
by
Briscoe RJ, Cabrera CL, Baird TJ, Rice KC, Woods JH.
Department of Pharmacology,
University of Michigan,
48109, Ann Arbor, MI, USA.
Brain Res 2000 Oct 27;881(2):204-7

ABSTRACT

Central administration of CRH results in endocrinological, cardiovascular, and behavioral effects that suggest stress or anxiety. Among these is a marked pressor response. Parenteral administration of CRH, however, results in hypotension. We used parenteral administration of antalarmin, a novel, small molecule CRH1 receptor antagonist, and alpha-helical CRH(9-41), a peptidic CRHR1/CRHR2 antagonist to attempt to determine the receptor mechanisms through which CRH is acting in both of these situations. Our results suggest that the hypertension produced by central CRH administration is mediated through central CRHR1 receptors, whereas the hypotension produced by parenteral CRH administration is mediated through peripheral CRHR2 receptors.

CRF
LHPA
R121919
Astressin
Antalarmin
Corticosteroids
Antalarmin and the mouse
CRF-1 receptor antagonists
Stress, depression and anxiety
Depression, opioids and the HPA
Antidepressants and new brain cells
CP-154,526, a non-peptide antagonist of the CRH1 receptor

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family